Industry news that matters to you.  Learn more

Archives for August 2017

Invivoscribe Releases LeukoStrat CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit

Invivoscribe® Technologies Inc., a global company with decades of experience providing clonality and biomarker test solutions for the fields of oncology and personalized molecular medicine®, today announces the release of the CE-marked IVD version of its LeukoStrat® CDx FLT3 Mutation Assay which earlier this year was approved by the FDA.